Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer

被引:2
|
作者
Zhou, Huijun [1 ]
Wu, Jie [2 ]
Shi, Lei [3 ]
Wang, Yu [1 ]
Liu, Bin [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Nucl Med, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
[2] Panzhihua Univ, Panzhihua Municipal Cent Hosp, Dept Nucl Med, Panzhihua, Sichuan, Peoples R China
[3] Chengdu Fifth Peoples Hosp, Dept Nucl Med, Chengdu, Sichuan, Peoples R China
来源
基金
中国博士后科学基金;
关键词
PTC; papillary thyroid cancer; timing of surgery; radioactive iodine; I-131; therapy; clinical outcomes; ADULT PATIENTS;
D O I
10.1210/clinem/dgac502
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The optimal timing to performing thyroid surgery following a diagnosis of papillary thyroid cancer (PTC) has yet to be fully defined. Objective We aimed to examine if a delayed surgery may worsen the clinical outcome of PTC patients with intermediate- to high-risk of recurrence. Methods All consecutive PTC patients with intermediate- to high-risk of recurrence who underwent total thyroidectomy and radioactive iodine (RAI) ablation at 3 tertiary hospitals in southwest China were retrospectively included. Excellent response at 1-year follow-up after initial therapy was defined as no clinical, imaging, or biochemical evidence of PTC. Association of the timing of surgery and excellent response rates. Results The study included 871 patients. The median time interval between PTC diagnosis and surgery was 2 months (range, 1-87 months). Patients were divided according to the timing of surgery, < 6 months (group A, 624/871 [71.6%]), >= 6 to 11 months (group B, 123/871 [14.1%]), or >= 12 months (group C, 124/871 [14.2%]). One year after initial therapy, 64.7%, 71.5%, and 66.1% of patients in groups A, B, and C, respectively, achieved excellent response (P = 0.27). The lack of impact of surgery timing was observed across intermediate- to high-risk classifications and all T stage categories. These findings did not change when we separately analyzed the groups according to RAI dose (intermediate-dose group: <= 3.7 GBq [n = 654], and high-activity group: 5.5 GBq [n = 217]) further subdivided according to the timing of surgery. Conclusion Timing of surgery does not seem to affect short-term disease outcomes in intermediate- to high-risk PTC patients. Further research is necessary to assess the impact of delayed surgery on long-term prognosis.
引用
收藏
页码:3389 / 3397
页数:9
相关论文
共 50 条
  • [1] Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma
    Kim, Mijin
    Han, Minkyu
    Jeon, Min Ji
    Kim, Won Gu
    Kim, In Joo
    Ryu, Jin-Sook
    Min, Won Bae
    Shong, Young Kee
    Kim, Tae Yong
    Kim, Bo Hyun
    CLINICAL ENDOCRINOLOGY, 2019, 91 (03) : 449 - 455
  • [2] Association between surgical extent and recurrence in unilateral intermediate- to high-risk papillary thyroid cancer
    Siyuan Xu
    Hui Huang
    Huilei Dong
    Xiaolei Wang
    Zhengang Xu
    Shaoyan Liu
    Jie Liu
    BMC Cancer, 23 (1)
  • [3] Association between surgical extent and recurrence in unilateral intermediate- to high-risk papillary thyroid cancer
    Xu, Siyuan
    Huang, Hui
    Dong, Huilei
    Wang, Xiaolei
    Xu, Zhengang
    Liu, Shaoyan
    Liu, Jie
    BMC CANCER, 2023, 23 (01)
  • [4] Incomplete response to therapy in intermediate- and high-risk thyroid cancer
    Ali S. Alzahrani
    Noha Mukhtar
    Endocrine, 2022, 78 : 531 - 542
  • [5] Incomplete response to therapy in intermediate- and high-risk thyroid cancer
    Alzahrani, Ali S.
    Mukhtar, Noha
    ENDOCRINE, 2022, 78 (03) : 531 - 542
  • [6] Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer
    Klubo-Gwiezdzinska, Joanna
    Auh, Sungyoung
    Gershengorn, Marvin
    Daley, Brianna
    Bikas, Athanasios
    Burman, Kenneth
    Wartofsky, Leonard
    Urken, Mark
    Dewey, Eliza
    Smallridge, Robert
    Chindris, Ana-Maria
    Kebebew, Electron
    JAMA NETWORK OPEN, 2019, 2 (02) : e187754
  • [7] Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer
    Bryant, Alex K.
    McKay, Rana R.
    Kader, A. Karim
    Parsons, J. Kellogg
    Einck, John P.
    Kane, Christopher J.
    Mundt, Arno J.
    Murphy, James D.
    Rose, Brent S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : 1068 - 1076
  • [8] Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus
    Lachant, Daniel
    Bach, Christina
    Wilson, Bennett
    Chengazi, Vaseem
    Goldman, Bruce
    Lachant, Neil
    Pietropaoli, Anthony
    Cameron, Scott
    James White, R.
    PULMONARY CIRCULATION, 2020, 10 (03)
  • [9] Localized intermediate- to high-risk prostate cancer
    Tritschler, S.
    Ganswindt, U.
    Stief, C. G.
    UROLOGE, 2016, 55 (03): : 318 - +
  • [10] Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
    Yu, Feng
    Li, Xue
    Ji, Yanhui
    Tan, Jian
    Zhang, Guizhi
    Wang, Peng
    He, Yajing
    Wang, Renfei
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12